Skip to Content
Merck
  • Novel key metabolites reveal further branching of the roquefortine/meleagrin biosynthetic pathway.

Novel key metabolites reveal further branching of the roquefortine/meleagrin biosynthetic pathway.

The Journal of biological chemistry (2013-11-15)
Marco I Ries, Hazrat Ali, Peter P Lankhorst, Thomas Hankemeier, Roel A L Bovenberg, Arnold J M Driessen, Rob J Vreeken
ABSTRACT

Metabolic profiling and structural elucidation of novel secondary metabolites obtained from derived deletion strains of the filamentous fungus Penicillium chrysogenum were used to reassign various previously ascribed synthetase genes of the roquefortine/meleagrin pathway to their corresponding products. Next to the structural characterization of roquefortine F and neoxaline, which are for the first time reported for P. chrysogenum, we identified the novel metabolite roquefortine L, including its degradation products, harboring remarkable chemical structures. Their biosynthesis is discussed, questioning the exclusive role of glandicoline A as key intermediate in the pathway. The results reveal that further enzymes of this pathway are rather unspecific and catalyze more than one reaction, leading to excessive branching in the pathway with meleagrin and neoxaline as end products of two branches.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tetramethylammonium chloride solution, for molecular biology
Sigma-Aldrich
Tetramethylammonium hydroxide pentahydrate, ≥95.0% (T)
Sigma-Aldrich
Tetramethylammonium hydroxide pentahydrate, ≥97%
Sigma-Aldrich
Tetramethylammonium iodide, 99%
Sigma-Aldrich
Hydroquinidine, 95%
Sigma-Aldrich
Tetramethylammonium chloride, BioUltra, for molecular biology, ≥99.0% (AT)
Sigma-Aldrich
Tetramethylammonium chloride, reagent grade, ≥98%
Sigma-Aldrich
Roquefortine C, ≥98% (HPLC), from Penicillium roqueforti